Gilead Sciences beats by $0.47, beats on revs; guides FY22 EPS above consensus (70.20 -0.62)
- Reports Q3 (Sep) earnings of $1.90 per share, excluding non-recurring items, $0.47 better than the S&P Capital IQ Consensus of $1.43; revenues fell 5.1% year/year to $7.04 bln vs the $6.13 bln S&P Capital IQ Consensus.
- Co issues upside guidance for FY22, sees EPS of $6.95-$7.15, excluding non-recurring items, (from $6.35-$6.75) vs. $6.52 S&P Capital IQ Consensus.
- Total product sales between $25.9 billion and $26.2 billion, compared to $24.5 billion and $25.0 billion previously.
- Total product sales, excluding Veklury, between $22.5 billion to $22.8 billion, compared to $22.0 billion and $22.5 billion previously.
- Total Veklury sales of approximately $3.4 billion, compared to approximately $2.5 billion previously.